MX389962B - Metodos para tratar trastornos mitocondriales y metabolicos. - Google Patents
Metodos para tratar trastornos mitocondriales y metabolicos.Info
- Publication number
- MX389962B MX389962B MX2019003397A MX2019003397A MX389962B MX 389962 B MX389962 B MX 389962B MX 2019003397 A MX2019003397 A MX 2019003397A MX 2019003397 A MX2019003397 A MX 2019003397A MX 389962 B MX389962 B MX 389962B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- metabolic disorders
- treating mitochondrial
- mitochondrial
- mtor inhibitor
- Prior art date
Links
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 230000002438 mitochondrial effect Effects 0.000 title abstract 2
- 208000012268 mitochondrial disease Diseases 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 208000006136 Leigh Disease Diseases 0.000 abstract 1
- 208000017507 Leigh syndrome Diseases 0.000 abstract 1
- 208000009564 MELAS Syndrome Diseases 0.000 abstract 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 abstract 1
- 208000013233 NARP syndrome Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nanotechnology (AREA)
- Neurosurgery (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
Abstract
La presente invención se refiere a métodos y composiciones para el tratamiento de enfermedades, tales como trastornos asociados a la mitocondria, por ejemplo síndrome de Leigh, MELAS, y NARP, y trastornos metabólicos, que comprenden administrar un inhibidor de mTOR alostérico, tal como una composición que comprende nanopartículas que comprenden un inhibidor de mTOR alostérico y una albúmina. También se proporcionan medicinas y kits útiles para los métodos descritos en la presente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662401092P | 2016-09-28 | 2016-09-28 | |
| PCT/US2017/054149 WO2018064405A1 (en) | 2016-09-28 | 2017-09-28 | Methods of treating mitochondrial and metabolic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019003397A MX2019003397A (es) | 2019-06-06 |
| MX389962B true MX389962B (es) | 2025-03-20 |
Family
ID=61763007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003397A MX389962B (es) | 2016-09-28 | 2017-09-28 | Metodos para tratar trastornos mitocondriales y metabolicos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190307732A1 (es) |
| EP (1) | EP3518923A4 (es) |
| JP (2) | JP2019529474A (es) |
| KR (2) | KR20230003239A (es) |
| CN (1) | CN110022876A (es) |
| AU (1) | AU2017335902B2 (es) |
| BR (1) | BR112019006113A2 (es) |
| CA (1) | CA3038824A1 (es) |
| CL (1) | CL2019000787A1 (es) |
| EA (1) | EA201990820A1 (es) |
| IL (1) | IL265566A (es) |
| MA (1) | MA46365A (es) |
| MX (1) | MX389962B (es) |
| WO (1) | WO2018064405A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2672618C (en) | 2006-12-14 | 2021-03-02 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| BR112012024590A2 (pt) | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| JP6987644B2 (ja) | 2015-06-29 | 2022-01-05 | アブラクシス バイオサイエンス， エルエルシー | 類上皮細胞腫瘍を処置する方法 |
| RU2020134124A (ru) | 2018-03-20 | 2022-04-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ |
| EP3810091A4 (en) * | 2018-05-22 | 2022-03-02 | Abraxis BioScience, LLC | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION |
| CN113795287A (zh) | 2019-03-19 | 2021-12-14 | 阿布拉科斯生物科学有限公司 | 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病 |
| WO2021086946A1 (en) | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| CN111621556A (zh) * | 2019-12-31 | 2020-09-04 | 安徽医科大学第一附属医院 | 一种检测人线粒体atp6基因8993位点基因型的试剂盒及方法 |
| CN111419876A (zh) * | 2020-04-30 | 2020-07-17 | 复旦大学附属中山医院 | 线粒体移植在治疗原发性扩心病中的应用 |
| CN112972681B (zh) * | 2021-01-27 | 2022-06-07 | 西安交通大学 | Mt-nd6作为新靶点在代谢综合征诊断和治疗药物中的应用 |
| CN114848795B (zh) * | 2021-02-03 | 2023-04-14 | 四川大学 | RORa蛋白及其激动剂在制备抗衰老药物中的应用 |
| CN114507677B (zh) * | 2022-02-16 | 2023-09-05 | 中国人民解放军空军军医大学 | Ndufs1基因在治疗心梗后心衰中的应用和相关产品 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7169594B2 (en) * | 2002-08-12 | 2007-01-30 | Regents Of The University Of Michigan | Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| EP1853610A1 (en) | 2005-03-03 | 2007-11-14 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
| US20090029904A1 (en) * | 2006-07-21 | 2009-01-29 | Sean Oldham | Compositions and methods for treatment of insulin-resistance diseases |
| KR20150002886A (ko) * | 2007-03-07 | 2015-01-07 | 아브락시스 바이오사이언스, 엘엘씨 | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 |
| CN101730526A (zh) * | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
| EP3326630A3 (en) * | 2007-05-03 | 2018-08-29 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
| ES2645692T3 (es) * | 2008-11-11 | 2017-12-07 | The Board Of Regents,The University Of Texas System | Microcápsulas de rapamicina y su uso para el tratamiento del cáncer |
| BR112012024590A2 (pt) * | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos |
| CA3063641A1 (en) * | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| WO2013024467A2 (en) | 2011-08-18 | 2013-02-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Mitochondrial ribosomal proteins as aging regulators |
| NZ630213A (en) * | 2013-03-14 | 2017-05-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| CA2929181A1 (en) * | 2013-11-13 | 2015-05-21 | Novartis Ag | Mtor inhibitors for enhancing the immune response |
| WO2016134486A1 (en) | 2015-02-27 | 2016-09-01 | Steinberg Gregory | Use of canagliflozin and derivatives thereof in the treatment of cancer |
| WO2017096270A1 (en) * | 2015-12-03 | 2017-06-08 | The Regents Of The University Of California | Methods for treating mitochondrial diseases |
| CN109073719A (zh) * | 2016-04-25 | 2018-12-21 | 皇家飞利浦有限公司 | 磁共振辐射屏蔽和被屏蔽的主磁体 |
-
2017
- 2017-09-28 CA CA3038824A patent/CA3038824A1/en active Pending
- 2017-09-28 AU AU2017335902A patent/AU2017335902B2/en active Active
- 2017-09-28 JP JP2019516447A patent/JP2019529474A/ja active Pending
- 2017-09-28 WO PCT/US2017/054149 patent/WO2018064405A1/en not_active Ceased
- 2017-09-28 KR KR1020227042293A patent/KR20230003239A/ko not_active Ceased
- 2017-09-28 MX MX2019003397A patent/MX389962B/es unknown
- 2017-09-28 MA MA046365A patent/MA46365A/fr unknown
- 2017-09-28 KR KR1020197011866A patent/KR102475256B1/ko active Active
- 2017-09-28 EA EA201990820A patent/EA201990820A1/ru unknown
- 2017-09-28 EP EP17857459.6A patent/EP3518923A4/en active Pending
- 2017-09-28 CN CN201780072508.4A patent/CN110022876A/zh active Pending
- 2017-09-28 US US16/336,390 patent/US20190307732A1/en not_active Abandoned
- 2017-09-28 BR BR112019006113A patent/BR112019006113A2/pt not_active Application Discontinuation
-
2019
- 2019-03-24 IL IL265566A patent/IL265566A/en unknown
- 2019-03-26 CL CL2019000787A patent/CL2019000787A1/es unknown
-
2022
- 2022-09-16 JP JP2022148199A patent/JP2022191238A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022191238A (ja) | 2022-12-27 |
| MX2019003397A (es) | 2019-06-06 |
| KR20190060797A (ko) | 2019-06-03 |
| KR102475256B1 (ko) | 2022-12-08 |
| EP3518923A1 (en) | 2019-08-07 |
| AU2017335902B2 (en) | 2023-08-24 |
| AU2017335902A1 (en) | 2019-04-18 |
| CN110022876A (zh) | 2019-07-16 |
| BR112019006113A2 (pt) | 2019-06-18 |
| JP2019529474A (ja) | 2019-10-17 |
| US20190307732A1 (en) | 2019-10-10 |
| MA46365A (fr) | 2019-08-07 |
| EP3518923A4 (en) | 2020-06-17 |
| CA3038824A1 (en) | 2018-04-05 |
| KR20230003239A (ko) | 2023-01-05 |
| IL265566A (en) | 2019-05-30 |
| WO2018064405A1 (en) | 2018-04-05 |
| CL2019000787A1 (es) | 2019-05-31 |
| EA201990820A1 (ru) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389962B (es) | Metodos para tratar trastornos mitocondriales y metabolicos. | |
| SA518391624B1 (ar) | Ror- منظمات جاما | |
| CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
| CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
| MX2019007586A (es) | Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares. | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| BR112015024530A2 (pt) | composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| MX2018013472A (es) | Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares. | |
| MX2016011810A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
| BR112015022545A2 (pt) | compostos de pirazolo e os usos disso | |
| BR112015016466A2 (pt) | método para o tratamento de câncer baseado no estado de mutação de k-ras | |
| MX2017016322A (es) | Metodos para tratar tumores de celulas epitelioides. | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| MX385762B (es) | Métodos para el control transcripcional objetivo en regiones del super mejorador. | |
| BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| UY35344A (es) | Oestra-1,3,5(10),16-tetraeno-3-carboxamidas | |
| TR201900148T4 (tr) | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. | |
| MX382175B (es) | Composiciones de profármaco de monometilfumarato | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. |